Last updated: September 9, 2026
The combination of diphenhydramine hydrochloride and naproxen sodium is a mature, over-the-counter analgesic and nighttime-symptom product category. Its commercial economics are driven by brand recognition, retail distribution, private-label pricing, seasonal demand, and regulatory compliance rather than by patent exclusivity. The closest major branded product is Bayer’s Aleve PM, although Aleve PM uses diphenhydramine citrate rather than diphenhydramine hydrochloride. That distinction affects product identification, regulatory filings, and patent analysis.
Standalone revenue for the exact diphenhydramine hydrochloride/naproxen sodium combination is not publicly reported. The market is fragmented across branded products, store brands, contract manufacturers, and retailer-specific labels.
What is the diphenhydramine hydrochloride and naproxen sodium combination?
Diphenhydramine hydrochloride is a first-generation antihistamine with sedating properties. Naproxen sodium is a nonsteroidal anti-inflammatory drug used for temporary relief of minor aches and pains.
The combination is intended to address nighttime pain where the consumer also seeks a sleep-aid effect. Typical product positioning includes:
| Component |
Primary function |
Commercial role |
| Naproxen sodium |
Analgesic and anti-inflammatory |
Pain-relief claim |
| Diphenhydramine hydrochloride |
Sedating antihistamine |
Nighttime or sleep-aid claim |
| Combination tablet |
Nighttime pain relief |
Convenience and premium positioning |
Aleve PM is the best-known adjacent branded product, but its active sleep-aid ingredient is diphenhydramine citrate, equivalent to 25 mg diphenhydramine, rather than diphenhydramine hydrochloride.[1] Products labeled with diphenhydramine hydrochloride may be generic, private-label, or separately approved products.
How large is the nighttime analgesic market?
The category is part of the broader U.S. consumer health market, which includes analgesics, sleep aids, antihistamines, gastrointestinal products, and cold remedies. Public financial reporting generally aggregates these categories rather than reporting revenue by active-ingredient combination.
Demand is supported by several structural factors:
- High prevalence of occasional musculoskeletal pain.
- Consumer preference for one-tablet nighttime products.
- Broad retail availability through pharmacies, mass merchants, supermarkets, club stores, and e-commerce.
- Low treatment cost compared with prescription pain or sleep medicines.
- Strong brand awareness for naproxen-based products.
Growth is limited by category maturity. Unit expansion is likely to be modest, while dollar growth depends on price increases, package-size changes, product renovation, and channel mix.
The main commercial pressure is substitution. Consumers can purchase naproxen sodium and diphenhydramine products separately, use acetaminophen-based nighttime products, or select ibuprofen/diphenhydramine combinations. Retailers also have a strong incentive to promote private-label equivalents at lower prices.
What is the financial trajectory for the product category?
The financial trajectory is mature and defensive rather than high-growth.
Revenue drivers
Revenue is determined by:
- Retail distribution and shelf placement.
- Brand price premium.
- Promotional intensity.
- Private-label share.
- Seasonal demand.
- E-commerce search visibility.
- Consumer switching among pain relievers.
A branded nighttime naproxen product can command a price premium over store brands because consumers recognize Aleve and associate naproxen with longer-lasting pain relief. That premium is vulnerable when retailers expand their private-label offerings or when inflation increases consumer price sensitivity.
Bayer exposure
Bayer reports Consumer Health revenue at the segment level rather than disclosing Aleve PM sales separately. Bayer’s Consumer Health division generates roughly €6 billion annually, with products spanning pain relief, dermatology, nutritional supplements, allergy, and digestive health.[2] Aleve is part of this wider portfolio, but the company does not publicly allocate revenue, gross margin, or operating profit to Aleve PM alone.
This makes exact product-level forecasting inappropriate. The reasonable financial interpretation is that Aleve PM contributes to a mature consumer-health portfolio, with economic value derived from brand equity and distribution rather than exclusivity.
Expected trajectory
| Period |
Likely market condition |
Financial effect |
| Near term |
Stable demand, price competition, retail promotions |
Revenue supported by pricing, margins pressured by promotions |
| Medium term |
Private-label expansion and ingredient substitution |
Unit share pressure for branded products |
| Longer term |
Limited category growth and regulatory scrutiny |
Cash-generative but low-growth profile |
A branded product can maintain attractive cash generation if it retains distribution and pricing power. The risk is gradual erosion rather than an abrupt patent cliff.
What patents protect diphenhydramine hydrochloride and naproxen sodium?
The active ingredients are old, established molecules with no meaningful composition-of-matter exclusivity remaining.
Naproxen was developed decades ago, and naproxen sodium is a salt form of the active ingredient. Diphenhydramine hydrochloride is also a long-established antihistamine. Any current protection would more likely involve:
- Specific dosage forms.
- Tablet coating or bilayer architecture.
- Modified-release delivery.
- Stability or manufacturing processes.
- Packaging systems.
- Product-specific labeling or method-of-use claims.
For a standard immediate-release combination tablet, patent protection is likely weak relative to the strength of the brand and regulatory positioning. Patent value would depend on whether a claim covers the exact active-ingredient ratio, dosage form, manufacturing process, or commercial product.
How many patents cover the combination?
No reliable conclusion should be drawn from a simple search for patents mentioning both ingredients. Patent documents may list the compounds in long ingredient lists without claiming the combination.
The relevant analysis requires separating:
| Patent category |
Likely relevance |
| Composition-of-matter patents |
No meaningful remaining protection expected |
| Combination formulation patents |
Potentially relevant if claims cover the exact ratio and tablet |
| Manufacturing patents |
Possible, but design-around risk is generally high |
| Method-of-use patents |
Limited value for broad OTC nighttime pain claims |
| Packaging patents |
Narrow commercial protection |
| Trademark rights |
Often more valuable than patent rights for branded OTC products |
What is the Orange Book status of the product?
The Orange Book primarily covers approved prescription and certain approved nonprescription drug applications. Products marketed under the FDA’s OTC monograph framework generally do not depend on an Orange Book-listed patent for market access.[3]
For the exact diphenhydramine hydrochloride/naproxen sodium product, the regulatory status depends on the product sponsor and marketing pathway:
- A monograph-compliant product may be marketed without an individual product-specific NDA.
- A branded combination may be supported by an NDA or an approved product application.
- A private-label product may rely on an approved manufacturer’s regulatory framework.
- An NDA-listed product may have Orange Book information, but the active ingredients themselves remain off-patent.
The distinction between diphenhydramine hydrochloride and diphenhydramine citrate is material. A patent or regulatory analysis for Aleve PM cannot automatically be applied to a hydrochloride-labeled product.
When does the combination lose exclusivity?
The combination has effectively lost active-ingredient exclusivity. There is no expected future composition-of-matter expiration event comparable to the loss of exclusivity for a new molecular entity.
Market entry is instead controlled by:
- FDA OTC monograph compliance.
- Manufacturing and quality requirements.
- Labeling compliance.
- Retailer qualification.
- Consumer trust.
- Trademark and trade-dress constraints.
For the branded product, commercial exclusivity can persist after patent expiry through brand loyalty, retail placement, and advertising. That protection is softer than patent exclusivity and can erode quickly when a retailer introduces a lower-priced equivalent.
Are there Paragraph IV challenges or generic litigation?
Paragraph IV litigation is primarily relevant to abbreviated new drug applications referencing listed prescription products with Orange Book patents. It is not the normal mechanism for a conventional OTC monograph product.
For this combination:
- No major Paragraph IV event is expected to define the market.
- Generic competition can enter through OTC pathways without waiting for a conventional patent cliff.
- Litigation risk is more likely to involve labeling, trademarks, trade dress, advertising, or manufacturing disputes.
- An NDA-based product could theoretically generate patent litigation, but no major public litigation trend is associated with the active ingredients themselves.
The absence of Paragraph IV litigation does not mean the market is protected. It means that competition is more likely to arise through regulatory and commercial channels.
What formulations are protected by patents?
Potentially protectable formulations include:
Immediate-release combination tablets
This is the most commercially common and technically accessible format. Patent strength is generally limited unless a sponsor can prove a novel ratio, dissolution profile, stability improvement, or manufacturing advantage.
Bilayer or multilayer tablets
A multilayer tablet could separate naproxen sodium from diphenhydramine or control disintegration. Such claims may have technical value, but competitors may design around them by using a conventional compressed tablet.
Modified-release naproxen formulations
A delayed or extended-release naproxen component could improve duration or tolerability. This would create a more defensible formulation position, but it would no longer be directly equivalent to a standard immediate-release OTC product.
Softgels and liquid-filled capsules
Softgels may provide differentiation in swallowability and dissolution. Their protection would likely center on formulation and manufacturing claims rather than the active ingredients.
Packaging and dose-control systems
Child-resistant packaging, blister formats, and unit-dose systems can support compliance and retail differentiation. They rarely create a high barrier to generic competition.
What regulatory risks affect the product?
The principal regulatory risk is safety labeling, not patent expiration.
Naproxen sodium carries NSAID-related risks, including gastrointestinal bleeding, cardiovascular events, renal effects, and interactions with other medicines. Diphenhydramine carries risks associated with sedation, impaired alertness, anticholinergic effects, and use in older adults. FDA labeling for OTC products addresses dosing limits, warnings, contraindications, and age restrictions.[4]
Commercial risks include:
- Consumer use with other NSAIDs.
- Concurrent use with other diphenhydramine-containing products.
- Use by older adults with elevated anticholinergic sensitivity.
- Drowsy driving or workplace impairment.
- Misleading claims about sleep, duration, or safety.
- Manufacturing deviations affecting strength or dissolution.
The combination’s regulatory burden is manageable but requires disciplined labeling and pharmacovigilance.
Which companies are challenging the branded product?
Competition comes from several groups rather than a single challenger:
| Competitor type |
Examples of competitive behavior |
| Retail private labels |
Lower-priced naproxen/diphenhydramine equivalents |
| Generic OTC manufacturers |
Contract manufacturing and national-brand supply |
| Alternative branded products |
Ibuprofen/diphenhydramine nighttime products |
| Single-ingredient products |
Separate naproxen and diphenhydramine purchases |
| E-commerce brands |
Search-driven, low-overhead private labels |
The strongest competitive threat is private label. A retailer can copy the active ingredients, dosage form, package size, and core consumer proposition while undercutting the branded product.
What is the generic launch risk?
Generic launch risk is high in commercial terms and low in litigation terms.
A technically compliant competitor can generally enter with limited development risk because:
- The ingredients are well characterized.
- The dosage form is conventional.
- The products are sold without prescription.
- Consumer switching costs are low.
- The market has established manufacturing infrastructure.
The main barriers are retailer access, quality consistency, packaging compliance, and advertising economics. A generic product does not need to win national brand recognition if it obtains placement in a major retail chain.
A likely launch pattern is gradual share capture through store brands rather than a single disruptive entry event.
How strong is the patent estate compared with competing nighttime analgesics?
The patent estate is weaker than the commercial brand position.
| Product category |
Active-ingredient patent strength |
Brand strength |
Entry risk |
| Naproxen/diphenhydramine nighttime product |
Low |
Medium to high for established brands |
High |
| Ibuprofen/diphenhydramine product |
Low |
Medium |
High |
| Acetaminophen/diphenhydramine product |
Low |
High in some brands |
High |
| Novel extended-release combination |
Potentially moderate |
Depends on launch |
Moderate |
| Prescription combination product |
May be higher |
Varies |
Depends on Orange Book estate |
Aleve PM’s commercial position is stronger than the underlying patent position because the Aleve trademark and retail presence support consumer demand after active-ingredient exclusivity has ended.
What licensing deals affect the combination?
No major public licensing transaction is necessary to explain the current market structure. The product category is supported by established active pharmaceutical ingredient suppliers, contract manufacturers, private-label arrangements, and retail distribution agreements.
Licensing value would be more likely in:
- A proprietary modified-release platform.
- A branded consumer-health acquisition.
- A regional distribution agreement.
- A private-label supply contract.
- A manufacturing or packaging technology transaction.
No standalone public transaction value should be attributed to the diphenhydramine hydrochloride/naproxen sodium combination without a product-specific disclosure.
What is the geographic coverage of the market?
The combination is most commercially relevant in the United States and other markets with established OTC self-care channels. Regulatory treatment differs by jurisdiction:
- The United States uses FDA OTC monographs and product-specific applications.
- The European Union applies national and centralized rules depending on the product and member state.
- Canada regulates nonprescription drugs through Health Canada monographs and product licensing.
- Other markets may classify the combination as pharmacy-only rather than general-sale OTC.
Geographic expansion is constrained by differences in approved indications, maximum daily doses, labeling language, combination-product rules, and the availability of diphenhydramine.
Key Takeaways
- Diphenhydramine hydrochloride plus naproxen sodium is a mature OTC nighttime analgesic combination.
- Aleve PM is the closest major branded comparator, but it uses diphenhydramine citrate rather than diphenhydramine hydrochloride.
- Active-ingredient patent protection is effectively exhausted.
- Commercial protection comes from trademarks, retail access, packaging, advertising, and consumer trust.
- Paragraph IV litigation is not the principal competitive mechanism.
- Private-label and generic entry risk is high, but market erosion is likely to be gradual.
- Bayer does not publicly disclose Aleve PM revenue separately from its broader Consumer Health segment.
- Financial performance should be modeled as mature, cash-generative, and exposed to pricing and private-label pressure.
- The principal regulatory risks involve NSAID safety, diphenhydramine sedation, labeling accuracy, and manufacturing quality.
FAQs
Is diphenhydramine hydrochloride the same as diphenhydramine citrate?
No. They are different salt forms of diphenhydramine. Both provide diphenhydramine as the pharmacologically active moiety, but the salt should be identified accurately in regulatory, patent, and product analyses.
Is Aleve PM protected by an active-ingredient patent?
No meaningful active-ingredient exclusivity should remain for naproxen sodium or diphenhydramine. Any surviving protection would depend on a specific formulation, manufacturing process, or product application.
Can retailers sell a private-label version of the combination?
Yes, provided the product complies with the applicable FDA regulatory pathway, labeling requirements, manufacturing standards, and other legal requirements.
Does the combination have biosimilar risk?
No. Biosimilar regulation applies to biologic products. Naproxen sodium and diphenhydramine hydrochloride are small-molecule drug ingredients.
What is the most important investment risk?
The primary risk is gradual branded-share erosion caused by private-label products, retailer bargaining power, promotional discounting, and substitution with other nighttime pain-relief products.
References
- Bayer HealthCare LLC. (n.d.). Aleve PM: Naproxen sodium and diphenhydramine citrate tablet, film coated. DailyMed, U.S. National Library of Medicine.
- Bayer AG. (2024). Annual report 2023. Bayer AG.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2023). Drug facts label: OTC pain relievers and fever reducers. FDA.
- Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.
- Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 338: External analgesic and sleep-aid drug products for over-the-counter human use.
